Kura Oncology (KURA) Collaboration summary

Opening remarks and agenda

• Kura Oncology and Kyowa Kirin announced a global strategic collaboration to develop and commercialize ziftomenib for acute leukemias, with a joint webcast and conference call held on November 20, 2024.

• Conference call introduced to discuss the partnership, with both companies' leadership outlining the collaboration and answering questions.

Objectives of the partnership

• Accelerate global development and commercialization of ziftomenib for AML and other hematologic malignancies, including expansion into combination therapies and post-transplant maintenance.

• Maximize benefit for patients and shareholders by leveraging both companies' strengths and securing funding to advance the ziftomenib AML program through to commercialization.

• Preserve strategic flexibility by retaining program leadership in the U.S. and key rights to ziftomenib and pipeline programs.

• Pursue potential solid tumor indications, including GIST, upon Kyowa Kirin opt-in.

Partner introductions and roles

• Kura leads U.S. development, regulatory, and commercial activities, booking sales and sharing profits 50/50 in the U.S.

• Kyowa Kirin leads regulatory and commercialization efforts outside the U.S., bringing global commercial expertise and booking ex-U.S. sales.

• Both companies share responsibility for global clinical trials and commercialization through a shared governance structure, with Kyowa Kirin potentially leading certain studies.